Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.89 0.00% 0.00
LXRX closed unchanged on Thursday, June 4, 2020, on 65 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical LXRX trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -1.05%
Bollinger Band Squeeze Range Contraction -1.05%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Biopharmaceutical Health Life Sciences Pharmaceutical Industry Diabetes Drug Discovery Monoclonal Antibodies Clinical Trial Rheumatoid Arthritis Glaucoma Ulcerative Colitis Irritable Bowel Syndrome Genentech Treatment Of Glaucoma Biotie Therapies Human Disease

Is LXRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.7101
52 Week Low 1.125
Average Volume 873,519
200-Day Moving Average 2.91
50-Day Moving Average 1.95
20-Day Moving Average 1.96
10-Day Moving Average 1.95
Average True Range 0.14
ADX 12.89
+DI 22.02
-DI 21.70
Chandelier Exit (Long, 3 ATRs ) 1.81
Chandelier Exit (Short, 3 ATRs ) 2.26
Upper Bollinger Band 2.10
Lower Bollinger Band 1.83
Percent B (%b) 0.23
BandWidth 13.68
MACD Line -0.02
MACD Signal Line -0.02
MACD Histogram -0.0072
Fundamentals Value
Market Cap 200.12 Million
Num Shares 106 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -1.42
Price-to-Sales 13.10
Price-to-Book 9.99
PEG Ratio -0.13
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.99
Resistance 3 (R3) 1.99 1.96 1.97
Resistance 2 (R2) 1.96 1.93 1.96 1.97
Resistance 1 (R1) 1.92 1.92 1.91 1.92 1.96
Pivot Point 1.89 1.89 1.88 1.89 1.89
Support 1 (S1) 1.86 1.87 1.84 1.86 1.82
Support 2 (S2) 1.83 1.85 1.83 1.81
Support 3 (S3) 1.79 1.83 1.81
Support 4 (S4) 1.79